FAQ on Clene's $7.3M Direct Offering and Private Placements

What is Clene Inc.?

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

How much did Clene raise in its recent offerings?

Clene raised an estimated $7.3 million from its registered direct offering and concurrent private placements, with the potential for additional capital through the future exercise of warrants.

Who participated in Clene’s recent funding?

The transactions involved a healthcare-focused institutional investor and existing shareholders, including insiders.

What will the raised funds be used for?

The funds will support Clene’s operations while it discusses with the FDA the potential filing of an NDA under the accelerated approval pathway by year end and continues its compassionate use programs for ALS patients.

What is CNM-Au8?

CNM-Au8 is an investigational, first-in-class therapy by Clene that aims to improve the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Where is Clene based?

Clene is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

How can I find more information about Clene?

For more information, visit Clene’s website at www.Clene.com or view the full press release at https://ibn.fm/diHO3.

What is the significance of the amendment to Clene’s existing debt facility?

The amendment to Clene’s existing debt facility with Avenue Venture Opportunities Fund, L.P., includes a debt principal deferral, providing the company with additional financial flexibility during its discussions with the FDA.